Skip to main content

Table 1 Selected Trials in Previously Untreated CLL Patients

From: Update in the management of chronic lymphocytic leukemia

Reference Regimen Phase No. Pts. CR, % ORR, % Median PFS (months)
Eichhorst, 2006 Flu III 164 7 83 20
  Flu + Cy   164 24 94 48
Flinn, 2007 Flu III 137 5 59 19
  Flu + Cy   141 23 74 32
Catovsky, 2007 Chl III 387 7 72 Not Rep
  Flu   194 15 80 Not Rep
  Flu + Cy   196 38 94 Not Rep
Byrd, 2003 FR (C) Rand. II 51 47 90 NR
  FR (S)   53 28 77 NR
Keating, 2005 FCR II 300 72 94 NR
Hallek, 2008 FC III 409 23 85 32
  FCR   408 45 93 43
Kay, 2007 PCR II 64 41 91 31
Kay, 2008 PR II 33 30 79 12
Reynolds, 2008 PCR III 92 7 45 Not Rep
  FCR   92 17 58 Not Rep
  1. Key: No-Number; Flu-fludarabine; CLB-Chlorambucil; Cy-cyclophosphamide; Ritux-rituximab; FR (C) – fludarabine + rituximab, concurrent; FR (S) – fludarabine + rituximab, sequential; FCR – fludarabine, cyclophosphamide, rituximab; PCR – pentostatin, cyclophosphamide, rituximab; PR – pentostatin + rituximab; CR – complete response rate; ORR – overall response rate; PFS – progression free survival; NR – not reached; Not Rep – Not reported